{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:13:24Z","timestamp":1777900404758,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.gore.2026.102064","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:45:18Z","timestamp":1774543518000},"page":"102064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary"],"prefix":"10.1016","volume":"64","author":[{"given":"Mackenzie W.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Herman","family":"Chui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa N.","family":"Kanbergs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hunter","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier","family":"Selenica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim A.","family":"Jungbluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara C.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Tarney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rois\u00edn E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102064_b0005","first-page":"446","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American Pathologists, American society for Clinical pathology, and the American society of clinical oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"JCO. Wolters Kluwer"},{"key":"10.1016\/j.gore.2026.102064_b0010","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/IGC.0b013e318228f6da","article-title":"Trop-2 overexpression in poorly differentiated endometrial endometrioid adenocarcinoma: Implications for immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody","volume":"21","author":"Bignotti","year":"2011","journal-title":"Int. J. Gynecol. Cancer: Official J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.gore.2026.102064_b0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2025.03.013","article-title":"Clinical applications of antibody drug conjugates for gynecologic malignancies: review of available medicines and emerging therapeutics","volume":"195","author":"Bujnak","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102064_b0020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41379-020-0642-9","article-title":"Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases","volume":"34","author":"Chapel","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.gore.2026.102064_b0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102064_b0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2025.03.023","article-title":"Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate","volume":"195","author":"Johannet","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102064_b0035","doi-asserted-by":"crossref","first-page":"560","DOI":"10.18632\/oncotarget.27342","article-title":"Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas","volume":"11","author":"Lopez","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.gore.2026.102064_b0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2024.06.008","article-title":"Folate receptor alpha expression in low-grade serous ovarian cancer: exploring new therapeutic possibilities","volume":"188","author":"Manning-Geist","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102064_b0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102064_b0050","first-page":"2162","article-title":"Mirvetuximab Soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"New Eng. J. Med. Massachusetts Medical Society"},{"key":"10.1016\/j.gore.2026.102064_b0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2025.04.590","article-title":"TROP2 expression and therapeutic targeting in uterine carcinosarcoma","volume":"197","author":"Moufarrij","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102064_b0060","first-page":"2789","article-title":"Trastuzumab Deruxtecan for human epidermal growth factor receptor 2\u2013expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"JCO. Wolters Kluwer"},{"key":"10.1016\/j.gore.2026.102064_b0065","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1007\/s12325-024-02975-x","article-title":"Efficacy of Trastuzumab Deruxtecan in HER2-expressing solid Tumors by Enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02","volume":"41","author":"Oaknin","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.gore.2026.102064_b0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ygyno.2025.03.021","article-title":"Anaplastic carcinoma of the ovary: a single-institution experience and molecular analysis","volume":"195","author":"Sullivan","year":"2025","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:30:42Z","timestamp":1777631442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"alternative-id":["S2352578926000445"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102064","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102064"}}